Disclosure of Cybersecurity Investments and the Cost of Capital
Information Systems Research · 2026-09 · 37 (3) · 1782-1804
DOI: 10.1287/isre.2023.0260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Information Systems Research, 2026-09. Verfasst von Taha Havakhor und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben.
Abstract (Originalsprache)
Executives often hesitate to disclose their company’s cybersecurity investments, fearing lawsuits or negative reactions from investors. Our research shows that transparency in this area actually pays off. Analyzing SEC filings from nearly 2,000 public firms, we find that companies that disclose cybersecurity investments enjoy a lower cost of capital—cheaper access to debt and equity financing. These benefits are strongest when disclosures are specific rather than boilerplate, when the firm is followed by more analysts and more institutional investors, and when disclosed investments in cybersecurity are substantial. The takeaway is clear: Meaningful disclosure builds trust with investors, who reward transparency by lowering financing costs. For leaders and regulators alike, this finding highlights that openness about cybersecurity readiness is not just good governance—It is smart business in a capital market that increasingly values risk management and resilience.
Zitieren
APA
Havakhor, T., Rahman, M. S., & Zhang, T. (2026). Disclosure of Cybersecurity Investments and the Cost of Capital. Information Systems Research, 37(3), 1782-1804. https://doi.org/10.1287/isre.2023.0260
Vancouver
Havakhor T, Rahman MS, Zhang T. Disclosure of Cybersecurity Investments and the Cost of Capital. Information Systems Research. 2026;37(3):1782-1804. doi:10.1287/isre.2023.0260
BibTeX
@article{Havakhor2026,
author = {Havakhor, Taha and Rahman, Mohammad S. and Zhang, Tianjian},
title = {Disclosure of Cybersecurity Investments and the Cost of Capital},
journal = {Information Systems Research},
year = {2026},
volume = {37},
number = {3},
pages = {1782--1804},
doi = {10.1287/isre.2023.0260}
}
EUVIMED